Ainos (AIMD) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Ainos Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ainos's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Ainos's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 17.38.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ainos's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.97.

Ainos Accounts Receivable Historical Data

The historical data trend for Ainos's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ainos Accounts Receivable Chart

Ainos Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.20

Ainos Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															0.11	0.01	-	-	-

Ainos Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Ainos Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Ainos's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.004	/	0.021	*	91
=	17.38

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ainos's accounts receivable are only considered to be worth 75% of book value:

Ainos's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.031	+	0.75 * 0.004	+	0.5 * 0.17	-	7.076
-	0	-	0)	/	6.14451
=	-0.97

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Ainos Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Ainos's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ainos (AIMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108

Website

https://www.ainos.com

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low dose oral form.

Executives

Meng Lin Sung	officer: Chief Financial Officer	8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee	director	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc	10 percent owner	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei	director	10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai	director, officer: Chairman, CEO, CFO	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai	director	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang	director	5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang	director	NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin	other: EVP - OPERATIONS	2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu	officer: Chief Financial Officer	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu	director	9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai	director	105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen	director	1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen	officer: VP, CFO	4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore	director	402 FISH HATCHERY ROAD, HAMILTON MT 59840